Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clene Inc (NQ: CLNN )

6.090 +0.270 (+4.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,388
Open 5.920
Bid (Size) 5.990 (1)
Ask (Size) 6.200 (1)
Prev. Close 5.820
Today's Range 5.500 - 6.140
52wk Range 3.818 - 14.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Does Multiple Sclerosis Reduce Risk of Developing Dementia?
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference
Via Investor Brand Network

Performance

YTD
+3.57%
+3.57%
1 Month
+19.18%
+19.18%
3 Month
-26.52%
-26.52%
6 Month
-31.42%
-31.42%
1 Year
-53.55%
-53.55%

More News

Read More
Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets
Via Investor Brand Network
Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Researchers Identify New Gene Behind ALS Onset
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials
Via Investor Brand Network
Exposures Product Safety
UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis
Via Investor Brand Network
Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA
Via Investor Brand Network
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation in Upcoming Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Discusses Important Developments of CNM-Au8(R) and Its Novel Technology During Xtalks Podcast
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference
Via Investor Brand Network
Study Suggests Vitamin B Deficiency Could Be Pivotal in Parkinson’s Disease
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Management Slated to Participate in Upcoming Emerging Growth Conference
Via Investor Brand Network
Gold Rises Sharply; Methode Electronics Shares Spike Higher
Via Benzinga
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.